GRAFFINITY SIGNS COLLABORATION AGREEMENT WITH ELI LILLY.Graffinity Pharmaceuticals, Heidelberg Heidelberg (hī`dəlbĕrkh), city (1994 pop. 139,430), Baden-Württemberg, SW Germany, picturesquely situated on the Neckar River. Manufactures include machinery, precision instruments, leather goods, and tobacco and wood products. , Germany, has entered into an agreement with Eli Lilly and company Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company and one of the world's largest corporations. Eli Lilly's global headquarters is located in Indianapolis, Indiana, in the United States. (NYSE NYSE See: New York Stock Exchange : LLY). Graffinity will utilize its novel chemical genomics technology, and drug fragment (1) In networking, one piece of a data packet that has been broken into smaller pieces in order to accommodate the maximum transmission unit (MTU) size of a network. See IP fragmentation. approach, to identify small molecule hit compounds against a selection of Lilly's therapeutic targets. Under the terms of this agreement Lilly will provide a selection of its drug targets to Graffinity. Graffinity will use its proprietary drug discovery platform, which is centered on chemical microarrays, drug fragment libraries, and label-free imaging of protein-ligand interactions, to identify novel hit compounds for a subset A group of commands or functions that do not include all the capabilities of the original specification. Software or hardware components designed for the subset will also work with the original. of the targets. "Novel screening and chemistry technologies that can both accelerate drug discovery and work across a range of targets are a vital part of modern drug discovery. We are excited about the opportunity to partner with a company of the stature stature /sta·ture/ (stach´ur) the height or tallness of a person standing.stat´ural stat·ure n. The height of a person. stature the height of an animal in the standing position. of Lilly which is at the forefront of innovative discovery approaches", said Victor Matassa, vice president of Research and Development of Graffinity. "The power of this technology is to rapidly generate valuable compound hits for the many drug targets identified from genomics research, and the partnership has the potential to generate long term value for Graffinity. Financial details were not disclosed. Graffinity Pharmaceuticals is a drug discovery company and leader in the emerging field of chemical genomics. Graffinity's chemical genomics platform combines new chemistry approaches, physics, information technology and microsystem technologies to screen potential drug targets. Of central importance is the combination of chemical microarrays with a proprietary method for the standardized standardized pertaining to data that have been submitted to standardization procedures. standardized morbidity rate see morbidity rate. standardized mortality rate see mortality rate. , label-free detection of compound-protein interactions. No assay development is necessary. Through Graffinity's RAISE (Rapid Affinity Informed Structure Evolution) process, small organic molecules are further developed in an evolutionary way directed by their interactions with proteins, both targets and non-targets, to deliver high quality, specific lead structures Graffinity has established collaborations with pharmaceutical and biotechnological partners, such as Pfizer, Aventis Pharma, Boehringer Ingelheim, Biosearch Italia, Celera, Merck KgaA This article needs sources or references that appear in reliable, third-party publications. Alone, primary sources and sources affiliated with the subject of this article are not sufficient for an accurate encyclopedia article. , m-phasys, and Structural GenomiX. The company, based in Heidelberg, Germany, was founded in 1998 and currently employs 100 people. For more information, visit http://www.graffinity.com. |
|
||||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion